Factbox-Sanofi takes page from rivals' separation playbook
Reuters
Published Oct 27, 2023 08:36
(Reuters) - Sanofi (EPA:SASY) on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shore up new drug development spending at its core business.
The French group's consumer business, which was put on course to be run on its own in late 2019, had 2022 sales of 5.1 billion euros ($5.4 billion), up 8.6%, with brand brands including Mucosolvan cough syrup, Allegra allergy treatments Buscopan against abdominal pain.
The following are similar recent transactions, or situations, at peers. * Consumer products maker Kenvue was spun off from Johnson &Johnson on May 4, 2023. With $15 billion in net sales in 2022,it is the world's largest pure-play consumer health company byrevenue. It owns brands such as Tylenol, Band-Aid and Listerine,spanning categories including pain killers, skin creams, menstrual hygiene, oral products and sunscreens. * Rival Haleon (LON:HLN) was spun off by GSK and Pfizer (NYSE:PFE) on July 182022. It had 2022 sales of 10.9 billion pounds ($13.2 billion).Its main focus is on over-the-counter drugs, such as Otrivinnasal decongestant and Voltaren against joint pain. About 42% ofsales come from toothpaste and other oral products as well asfrom dietary supplements such as vitamins and minerals. * Bayer (ETR:BAYGN), led by new CEO Bill Anderson since June, has facedcalls by several investors to sell or spin off its ConsumerHealth business but has not announced such plans.Accounting forabout 12% of group revenue, that unit had 6.08 billion euros in2022 sales, up 14.9%. Brands include Claritin allergy relief,pain killers Aspirin and Aleve as well as Afrin nasaldecongestant. * In a further transaction by a major drugmaker honing inexclusively on developing innovative drugs, Novartis (LON:0QLR) spun offgeneric and biosimilar drugs business Sandoz (SIX:SDZ) on Oct. 4.The newcompany, with $9.2 billion in 2022 sales, was initially valuedat a lower-than-expected 10.3 billion Swiss francs ($11.2billion) on its stock market debut.
Get The App
($1 = 0.9473 euros)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.